PRKCI and cancer: Aurothiomalate (ATM) forms a thio-gold adduct with a cysteine residue within the Phox-Bem1 (PB1) domain of PKCι (Cys69), thereby blocking PB1 domain-mediated interactions with components of PKCι's pro-cancer signaling complex, and inhibiting PKCι oncogenic function [4].